SONN logo

SONN Stock Overview

Profile

Full Name:

Sonnet BioTherapeutics Holdings, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

October 31, 2006

Indexes:

Not included

Description:

Sonnet BioTherapeutics Holdings is a biotechnology company focused on developing innovative therapies for cancer and other diseases. They use a unique platform to create targeted treatments that aim to improve patient outcomes and reduce side effects, making healthcare more effective and accessible.

Key Details

Price

$1.64

Annual Revenue

$18.60 K(-87.42% YoY)

Annual EPS

-$11.35(+92.18% YoY)

Annual ROE

1531.23%

Beta

0.34

Events Calendar

Earnings

Next earnings date:

Feb 14, 2025

Recent quarterly earnings:

Dec 17, 2024

Recent annual earnings:

Dec 17, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Sep 30, 2024

Analyst ratings

Recent major analysts updates

Dec 20, 24 Chardan Capital
Buy
Aug 23, 24 Chardan Capital
Buy
May 28, 24 Chardan Capital
Buy
May 16, 24 EF Hutton
Buy
Feb 15, 24 Chardan Capital
Buy
Nov 27, 23 Ladenburg Thalmann
Buy
Aug 16, 23 Chardan Capital
Buy
Jun 26, 23 EF Hutton
Buy
May 11, 23 Chardan Capital
Buy
Apr 19, 23 EF Hutton
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment
Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment
Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment
SONN
globenewswire.comDecember 23, 2024

PRINCETON, NJ, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced the next CEO Corner segment has been published on the Company's website .

Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
SONN
globenewswire.comDecember 17, 2024

Continued progress with both clinical trials of lead program, SON-1010, for solid tumors and Platinum-Resistant Ovarian Cancer (PROC)

Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates
Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates
Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates
SONN
globenewswire.comNovember 6, 2024

Both novel bifunctional (SON-1411) and monofunctional (SON-1400) fusion proteins exhibit wild-type binding to the IL-18 receptor (IL-18Rc), coupled with undetectable binding to the inhibitory IL-18 binding protein (IL-18BP)

Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs
Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs
Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs
SONN
globenewswire.comOctober 4, 2024

PRINCETON, NJ, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced it has received preliminary approval for a tax credit from the New Jersey Technology Business Tax Certificate Transfer Program administered by the New Jersey Economic Development Authority (NJEDA). Sonnet received approval of its application to sell up to $8,143,144 of its New Jersey State net operating losses (NOLs) and $62,810 of its New Jersey State research and development (R&D) tax credits for proceeds of up to $0.795 million through the New Jersey Technology Business Tax Certificate Transfer Program, subject to execution of such sale. Sonnet also expects to receive a $0.7 million net cash refund from the R&D Tax Incentive Program in Australia.

Sonnet BioTherapeutics Announces Launch of CEO Corner Platform
Sonnet BioTherapeutics Announces Launch of CEO Corner Platform
Sonnet BioTherapeutics Announces Launch of CEO Corner Platform
SONN
globenewswire.comSeptember 30, 2024

CEO Corner segments to include additional discussion related to press releases, events, corporate updates and pipeline progress

Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split
Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split
Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split
SONN
globenewswire.comSeptember 25, 2024

PRINCETON, N.J., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (“Sonnet” or the “Company”) (NASDAQ: SONN), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that it will effect a 1-for-8 reverse stock split of its outstanding common stock. This will be effective for trading purposes as of the commencement of trading on Monday, September 30, 2024.

Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series
Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series
Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series
SONN
globenewswire.comSeptember 4, 2024

PRINCETON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced that it will participate in the Virtual Investor Closing Bell Series on Monday, September 9, 2024, at 4:00 PM ET.

Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
SONN
globenewswire.comAugust 14, 2024

Ongoing progress with both clinical trials of lead program, SON-1010, for solid tumors and Platinum-Resistant Ovarian Cancer (PROC)

Sonnet BioTherapeutics (NASDAQ:SONN) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team
Sonnet BioTherapeutics (NASDAQ:SONN) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team
Sonnet BioTherapeutics (NASDAQ:SONN) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team
SONN
accesswire.comJuly 24, 2024

Watch the "What This Means" segment here FRENCHTOWN, NJ / ACCESSWIRE / July 24, 2024 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today released a Virtual Investor "What This Means" segment featuring Sonnet BioTherapeutics, Inc. (Nasdaq:SONN), a clinical-stage company developing targeted immunotherapeutic drugs. As part of the "What This Means" segment, Pankaj Mohan, PhD, Founder and Chief Executive Officer, Richard Kenney, M.D.

Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting
Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting
Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting
SONN
globenewswire.comMay 28, 2024

PRINCETON, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that the SB221 study of SON-1010 (recombinant human Interleukin-12 linked to Sonnet's fully-human albumin binding domain or IL12-FHAB) dosed in combination with atezolizumab (Tecentriq®) will be presented as a ‘Trial in Progress' poster at ASCO 2024. Study SB221 (NCT05756907) is a Phase 1b/2a multicenter, dose-escalation, and proof-of-concept clinical study to assess the safety, tolerability, PK, PD, and efficacy of SON-1010 administered SC, either alone or in combination with a fixed dose of atezolizumab given IV. The work will be presented in a poster session at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting 2024, to be held May 31 to June 4 in Chicago, Illinois.

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the ticker symbol for Sonnet BioTherapeutics Holdings?
  • Does Sonnet BioTherapeutics Holdings pay dividends?
  • What sector is Sonnet BioTherapeutics Holdings in?
  • What industry is Sonnet BioTherapeutics Holdings in?
  • What country is Sonnet BioTherapeutics Holdings based in?
  • When did Sonnet BioTherapeutics Holdings go public?
  • Is Sonnet BioTherapeutics Holdings in the S&P 500?
  • Is Sonnet BioTherapeutics Holdings in the NASDAQ 100?
  • Is Sonnet BioTherapeutics Holdings in the Dow Jones?
  • When was Sonnet BioTherapeutics Holdings's last earnings report?
  • When does Sonnet BioTherapeutics Holdings report earnings?
  • Should I buy Sonnet BioTherapeutics Holdings stock now?

What is the ticker symbol for Sonnet BioTherapeutics Holdings?

The ticker symbol for Sonnet BioTherapeutics Holdings is NASDAQ:SONN

Does Sonnet BioTherapeutics Holdings pay dividends?

No, Sonnet BioTherapeutics Holdings does not pay dividends

What sector is Sonnet BioTherapeutics Holdings in?

Sonnet BioTherapeutics Holdings is in the Healthcare sector

What industry is Sonnet BioTherapeutics Holdings in?

Sonnet BioTherapeutics Holdings is in the Biotechnology industry

What country is Sonnet BioTherapeutics Holdings based in?

Sonnet BioTherapeutics Holdings is headquartered in United States

When did Sonnet BioTherapeutics Holdings go public?

Sonnet BioTherapeutics Holdings's initial public offering (IPO) was on October 31, 2006

Is Sonnet BioTherapeutics Holdings in the S&P 500?

No, Sonnet BioTherapeutics Holdings is not included in the S&P 500 index

Is Sonnet BioTherapeutics Holdings in the NASDAQ 100?

No, Sonnet BioTherapeutics Holdings is not included in the NASDAQ 100 index

Is Sonnet BioTherapeutics Holdings in the Dow Jones?

No, Sonnet BioTherapeutics Holdings is not included in the Dow Jones index

When was Sonnet BioTherapeutics Holdings's last earnings report?

Sonnet BioTherapeutics Holdings's most recent earnings report was on Dec 17, 2024

When does Sonnet BioTherapeutics Holdings report earnings?

The next expected earnings date for Sonnet BioTherapeutics Holdings is Feb 14, 2025

Should I buy Sonnet BioTherapeutics Holdings stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions